ACC Announces Late-Breaking Trial Presentations


February 7, 2014
American College of Cardiology Clinical Trial Cath Lab EP Cardiac Diagnostics
February 7, 2014 — Results from several late-breaking clinical trials will be presented during  the American College of Cardiology (ACC) 2014 annual meeting March 29-31. These will be featured during five late-breaking clinical trial sessions. 
Joint ACC/JACC Late-Breaking Clinical Trials
Session 451, Saturday, March 29, 8–10 a.m., Hall D (Main Tent)
  • A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis Deemed High-Risk for Surgery
  • The main results of SYMPLICITY HTN-3 renal denervation trial
Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials
Session 402, Sunday, March 30, 8–9:15 a.m., Hall D (Main Tent)
  • Effect of Inhibition of Lipoprotein-Associated Phospholipase A2 with Darapladib on Ischemic Events in Patients with Chronic Coronary Heart Disease: The STABILITY (STabilisation of Atherosclerotic plaque By Initiation of darapLadIb TherapY) Trial
  • The Low-density Lipoprotein Cholesterol Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy - 2 Trial: A Phase 3, Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Combination With Statin Therapy in Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia
  • Evaluation of the Dual PPAR-α/γ Agonist Aleglitazar to Reduce Cardiovascular Events in Patients with Acute Coronary Syndrome and Type 2 Diabetes Mellitus: the AleCardio Trial
  • Two-year Outcome of a Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer: the Nobori Biolimus-Eluting versus Xience/Promus Everolimus-eluting Stent Trial (NEXT)
  • A Phase 3 Double-blind, Randomized Study to Assess the Safety and Efficacy of Evolocumab (AMG 145) in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of Statin
Late-Breaking Clinical Trials III
Session 403, Sunday, March 30, 10:45 a.m.–noon, Hall D (Main Tent)
  • Efficacy And Safety Of Colchicine In Patients With Multiple Recurrences Of Pericarditis: Results Of A Multicenter, Double-blind, Placebo-controlled, Randomized Study (corp-2 Trial)
  • The Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension
  • One Year Follow-up of the Melody Transcatheter Pulmonary Valve Multicenter Post Approval Study
  • Long-term Survival with Cardiac Resynchronization Therapy in Patients with Mild Heart Failure
  • Negative High-Sensitive Troponins in the Emergency Department and Risk of Myocardial Infarction
Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials
Session 404, Monday, March 31, 8–9:15 a.m., Hall D (Main Tent)
  • The Impact of Acetyl-Salicylic Acid on Major Arterial and Venous Complications in Patients Undergoing Noncardiac Surgery
  • A Large International Trial Assessing the Effects of Clonidine on Major Arterial Events in Patients Having Noncardiac Surgery
  • Steroids in Cardiac Surgery Trial (SIRS)
  • Metformin in Acute Myocardial Infarction
  • Effect of Bariatric Surgery vs. Intensive Medical Therapy on Long-term Glycemic Control and Complications of Diabetes: 3-Year STAMPEDE Trial Results
Late-Breaking Clinical Trials V: TCT@ACC-i2
Session 405, Monday, March 31, 10:45 a.m.–noon, Hall D (Main Tent)
  • One Year Outcomes from the STS/ACC Transcatheter Valve Therapy (TVT) Registry
  • A Randomized Comparison of Self-Expandable and Balloon-Expandable Prostheses in Patients Undergoing Transfemoral Transcatheter Aortic Valve Replacement - The CHOICE Trial
  • Unfractionated Heparin versus Bivalirudin in Primary Percutaneous Coronary Intervention: A Unique Randomized Controlled Trial with Consecutive, Unselected Patient Enrollment (using Delayed Consent), Designed to Reflect Real-World, Contemporary Practice
  • Bare Metal vs. Zotarolimus-eluting stent in Uncertain Drug-eluting Stent Candidates: A Randomized Controlled Trial
  • Autotransplantation of Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Severe Ischemic Heart Failure: The MSC-HF Trial
Late-Breaking Clinical Sessions Deep Dive
Session 406, Monday, March 31, 10:45 a.m.–12:15 p.m., Hall D (Main Tent)
  • Hear key highlights of the LBCTs presented throughout ACC.14 and learn about what it all means for you and your patients
For more information:
The content of this field is kept private and will not be shown publicly.
Type the characters you see in this picture. (verify using audio)
Type the characters you see in the picture above; if you can't read them, submit the form and a new image will be generated. Not case sensitive.